Skip to content

Exercise Training Using an App on Physical Cardiovascular Function Individuals With Post-covid-19 Syndrome

Effects of a Physical Training Program Using a Mobile App on the Functionality and Cardiovascular Function of Individuals With Post-covid-19 Syndrome: Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06168006
Acronym
Recovery
Enrollment
60
Registered
2023-12-13
Start date
2024-03-01
Completion date
2026-06-30
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Acute COVID-19 Syndrome

Keywords

exercise, mobile app, physical function, cardiovascular function

Brief summary

The aim of this study is to assess the effect of a physical exercise program via a mobile application on functional parameters in individuals with post-COVID-19 syndrome. This is a clinical trial involving 60 individuals with post-COVID syndrome who will be randomly assigned to either a control group (physical activity guideline) or an experimental group (app-based training).

Interventions

BEHAVIORALExercise

The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.

BEHAVIORALControl

They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.

Sponsors

University of Nove de Julho
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcomes assessor will be blinded for the group of the subjects

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Laboratory diagnosis of COVID-19 * Fatigue ≥ 8 points on the Chalder Scale and/or dyspnea 2-4 on the Modified Medical Research Council * Have access to a smartphone * Have no contraindications for exercise practice * Have ability to sit and stand and maintain balance while standing * Have preserved cognitive function * Have no risk of falls according to the Morse Fall Scale

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in 6 min-walk test distance at 12 weeksBaseline and 12 weeksThe 6-minute walk test performed in a 30-meter corridor, measured in meters
Change from baseline in Glittre test at 12 weeksBaseline and 12 weeksThe test consists in rise from a chair, carry a weighted backpack, walk 10 meters, climb stairs, move objects between shelves (1 kg each), and return. They perform tasks sequentially, transferring items up and down shelves. The route is retraced, ending by sitting back in the initial chair, measured in seconds
Change from baseline in sit and stand test at 12 weeksBaseline and 12 weeksThe test consists in rising from a chair as many times as possible within 30 seconds, measured in number of repetitions
Change from baseline in Post-Covid Functional Scale at 12 weeksBaseline and 12 weeksThe Post-COVID-19 Functional Status Scale assesses limitations following SARS-CoV-2 infection, measured as a score

Secondary

MeasureTime frameDescription
Change from baseline in Patient Functional Scale at 12 weeksBaseline and 12 weeksThe Patient Functional Scale allows individuals to identify 3 to 5 important activities they consider themselves unable to perform or are having difficulty with due to their condition, measured in a score
Change from baseline in Motor Evoked Potential at 12 weeksBaseline and 12 weeksThe cortical excitability of the quadriceps motor area will be measured using Motor Evoked Potential results in microvolts (µV) using the Transcranial Magnetic Stimulation equipment model MagPro R20 (MagVenture, Denmark) with the parabolic coil model MMC-140-II, measured in kgf
Change from baseline in Modified Medical Research Dyspnea Scale at 12 weeksBaseline and 12 weeksThis scale comprises five items, allowing the patient to select the item that corresponds to how much their dyspnea limits their daily life activities, measured as a score
Change from baseline in Chalder Physical Fatigue Scale at 12 weeksBaseline and 12 weeksComprising eight specific statements about physical fatigue to confirm its presence or absence, measured as a score
Change from baseline in De Paul Symptom Questionnaire at 12 weeksBaseline and 12 weeksThe questionnaire evaluate the symptoms of fatigue in different conditions, measured as a score
Change from baseline in Quality of Life at 12 weeksBaseline and 12 weeksTo assess quality of life, the 12-Item Short-Form Health Survey will be used, consisting of twelve items that evaluate eight different dimensions influencing quality of life, measured as a score
Change from baseline in Frailty and Sarcopenia at 12 weeksBaseline and 12 weeksFrailty will be assessed using the Tilburg Frailty Indicator, while sarcopenia will be evaluated through the Sarcopenia Form questionnaire, both measured as a score
Change from baseline in Anxiety and Depressive Symptoms at 12 weeksBaseline and 12 weeksLevels of anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale, measured as a score
Change from baseline in Pain at 12 weeksBaseline and 12 weeksAssessed using the Numeric Pain Rating Scale, measured as a score
Change from baseline in Movement Behavior at 12 weeksBaseline and 12 weeksMovement behavior will be quantified through a motion sensor, measured in minutes
Change from baseline in Barriers to Physical activity at 12 weeksBaseline and 12 weeksSpecific questionnaire to assess the most prevalent environmental barriers to physical activity, measured as presence or absence
Post assessment of Exercise Adherence Assessment Scale12 weeksAdherence to exercise interventions will be obtained with the Adherence Assessment Scale
Change from baseline in Blood Pressure at 12 weeksBaseline and 12 weeksThe clinical resting blood pressure will be assessed using automatic blood pressure monitoring equipment (HEM-7113, OMRON®, Brazil), measured in mmHg
Change from baseline in Cardiac Autonomic Modulation at 12 weeksBaseline and 12 weeksCardiac autonomic modulation will be assessed through heart rate variability using a heart rate monitor, measured in RR intervals
Change from baseline in Blood Flow and Flow-mediated Dilation at 12 weeksBaseline and 12 weeksThe measurements of basal blood flow and flow-mediated vasodilation will be obtained through ultrasonography in brachial artery, measured in ml/min or %
Change in Spirometry parameters at 12 weeksBaseline and 12 weeksChanges in Forced vital capacity, forced expiratory volume in the first second, Peak expiratory flow, forced expiratory flow 25-75% and FEV 1 /FVC ratio

Countries

Brazil

Contacts

CONTACTRaphael Ritti-Dias, PhD
raphaelritti@gmail.com+55 19 99940 6878
CONTACTFernanda Corrêa, PhD
fecorrea@uninove.br+55 11 97344-0380
PRINCIPAL_INVESTIGATORFernanda Corrêa, PhD

University of Nove de Julho

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026